AMRA Medical Earns TIME’s Highest “Outstanding” Rating in World’s Top HealthTech Companies 2026

Contributed by: Business Wire

Logo

Tags

Other Health

Research

General Health

Radiology

Pharmaceutical

Biometrics

Health Technology

Clinical Trials

Science

Biotechnology

Other Science

Health

TIME’s Highest “Outstanding” Rating

More Like This

AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’

Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’

New Year, New Solutions: AMRA Medical Continues Commitment to Innovation & Data-Driven Excellence

AMRA® Profiler 4 provides rapid and precise body composition measurements in relation to normative data, contextualizing insights at the individual patient level, with high accuracy. (Graphic: Business Wire)

AMRA Medical Secures European Medical Device Regulation Certificate for AMRA® Profiler 4, Highlighting Yet Another Regulatory Win

HealthCap Invests in AMRA Medical to Accelerate Global Growth in Quantitative MRI

HealthCap Invests in AMRA Medical to Accelerate Global Growth in Quantitative MRI

AMRA's muscle biomarkers - Research study explore changes in lean muscle volume (LMV), muscle fat fraction (MFF), and muscle fat infiltration (MFI)

Decoding Duchenne Muscular Dystrophy: MRI Study Explores the Relationship Between AMRA’s Muscle Biomarkers and Functional Changes in Individuals With DMD

Advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment

Advanced MRI Imaging Reveals Changes in Muscle Composition and Fat Infiltration During Obesity Treatment

A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol (Photo: Business Wire)

Baseline Enrollment Completed for AMRA Medical and Linköping University’s Landmark Liver Disease Study

Credit: Collaboration with Dr. Ian J Neeland, University Hospitals Cleveland. Data from NCT03038620 (ClinicalTrials.gov identifier) analysed with AMRA® Researcher

AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity